alexa
Reach Us +44-1235425476
Patient Specific 3D Image-Based Radiation Dose Estimates for 90Y Microsphere Hepatic Radioembolization in Metastatic Tumors | OMICS International | Abstract
ISSN: 2155-9619

Journal of Nuclear Medicine & Radiation Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Special Issue Article

Patient Specific 3D Image-Based Radiation Dose Estimates for 90Y Microsphere Hepatic Radioembolization in Metastatic Tumors

Andrew Kennedy1,2*, William Dezarn3 and Alec Weiss3

1Co-Medical Director, Wake Radiology Oncology, 300 Ashville Ave., Suite 110, Cary, NC, 27518 USA

2Adjunct Associate Professor, Department of Biomedical Engineering, Department of Mechanical and Aerospace Engineering, North Carolina State University, Raleigh, NC, USA

3Department of Biologic Systems Engineering, Campus Box 7910, Broughton Hall 4160, North Carolina State University, Raleigh, NC 27695-7910 USA

*Corresponding Author:
Andrew Kennedy, MD
FACRO, Wake Radiology Oncology
300 Ashville Ave., Suite 110, Cary, North Carolina 27518
Tel: (919) 854-4588
Fax: (919) 854-9950
E-mail: [email protected]

Received date: April 26, 2011; Accepted date: May 26, 2011; Published date: June 15, 2011

Citation: Kennedy A, Dezarn W, Weiss A (2011) Patient Specific 3D Image-Based Radiation Dose Estimates for 90Y Microsphere Hepatic Radioembolization in Metastatic Tumors. J Nucl Med Radiat Ther 2:111. doi: 10.4172/2155-9619.1000111

Copyright: © 2011 Kennedy A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Introduction: Hepatic brachytherapy using either resin or glass 90Y microspheres is an established therapy for unresectable primary and metastatic tumors. Unlike conventional brachytherapy, microsphere brachytherapy has no software currently available for pretreatment evaluation and radiation planning. A non-MIRD radiation dose calculation approach is desired to accurately utilize spatial relationships in the liver and tumor distribution. Materials and methods: A newly developed software tool employing the technetium-99m macro aggregated albumin (99mTc-MAA) SPECT 3-D dataset and CT scan was used to estimate the likely absorbed dose in normal liver and tumor tissue from 90Y microsphere brachytherapy (radioembolization). Monte Carlo algorithms were utilized to maximize true 3D dose estimates for each patient's unique liver and tumor geometry. Clinical correlation was completed regarding toxicity, imaging response, and complications as an independent measure of the software's usefulness in predicting radiation effects. Comparisons were made to MIRD, Body Surface Area method, and physician prescription for 90Y activity. Results: The software performed accurately in estimating absorbed dose in phantom testing. Patient data from 50 consecutive patients with metastatic tumors (26 colon, 24 neuroendocrine) to the liver receiving 59 radioembolization treatments were studied. The software estimate of median normal liver and tumor absorbed doses were 27.6 Gy and 41.2 Gy, respectively. Conclusions: The use of pretreatment 99mTc-MAA SPECT co-registered to a CT scan provides useful and unique data for a newly developed non-MIRD, Monte Carlo-based radiation dosimetry software program in 90Y microsphere brachytherapy. Software estimates of radiation dose preserving critical spatial information in the liver and tumors appeared reasonable based on clinical outcomes. Further testing and refinement of the software interface is ongoing with plans to distribute it to research organizations.

Keywords

Recommended Conferences

Clinical Oncology & Radiation Therapy

Singapore, Singapore
Share This Page
Top